{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:10:28Z","timestamp":1789495828884,"version":"build-2803163510"},"reference-count":110,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.survophthal.2025.09.024","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T23:08:00Z","timestamp":1759360080000},"page":"674-684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Medical and surgical approaches to prevent corneal graft rejection in high-risk recipients"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4457-8077","authenticated-orcid":false,"given":"Sepehr","family":"Feizi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firouze","family":"Hatami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina Khosravi","family":"Mirzaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kia","family":"Bayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.survophthal.2025.09.024_bib1","article-title":"Immunosuppressants for the prophylaxis of corneal graft rejection after penetrating keratoplasty","volume":"2015","author":"Abudou","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.survophthal.2025.09.024_bib2","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/bjophthalmol-2020-316705","article-title":"Corneal graft failure: an update","volume":"105","author":"Alio","year":"2021","journal-title":"Br J Ophthalmol"},{"issue":"2-3","key":"10.1016\/j.survophthal.2025.09.024_bib3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanisms of action","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"issue":"7114","key":"10.1016\/j.survophthal.2025.09.024_bib4","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nature05249","article-title":"Corneal avascularity is due to soluble VEGF receptor-1","volume":"443","author":"Ambati","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.survophthal.2025.09.024_bib5","article-title":"Machine learning to analyze factors associated with ten-year graft survival of keratoplasty for cornea endothelial disease","volume":"9","author":"Ang","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.survophthal.2025.09.024_bib6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/bjophthalmol-2015-306837","article-title":"Descemet membrane endothelial keratoplasty","volume":"100","author":"Ang","year":"2016","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"10.1016\/j.survophthal.2025.09.024_bib7","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1097\/TP.0000000000002938","article-title":"High-risk corneal transplantation: recent developments and future possibilities","volume":"103","author":"Armitage","year":"2019","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.survophthal.2025.09.024_bib8","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bjophthalmol-2020-317543","article-title":"Corneal transplant Follow-up study II: a randomised trial to determine whether HLA class II matching reduces the risk of allograft rejection in penetrating keratoplasty","volume":"106","author":"Armitage","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.09.024_bib9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ajo.2020.11.006","article-title":"Comparative study of long-term graft survival between penetrating keratoplasty and deep anterior lamellar keratoplasty","volume":"224","author":"Arundhati","year":"2021","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2025.09.024_bib10","doi-asserted-by":"crossref","first-page":"269","DOI":"10.14740\/jocmr2326w","article-title":"Systemic immunosuppression in high-risk penetrating keratoplasty: a systematic review","volume":"8","author":"Bali","year":"2016","journal-title":"J Clin Med Res"},{"issue":"3","key":"10.1016\/j.survophthal.2025.09.024_bib11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.preteyeres.2012.02.003","article-title":"Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye disease","volume":"31","author":"Barabino","year":"2012","journal-title":"Prog Retin Eye Res"},{"issue":"6","key":"10.1016\/j.survophthal.2025.09.024_bib12","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/00003226-200308000-00013","article-title":"Long-term outcome in high-risk corneal transplantation and the influence of HLA-A and HLA-B matching","volume":"22","author":"Bartels","year":"2003","journal-title":"Cornea"},{"issue":"12","key":"10.1016\/j.survophthal.2025.09.024_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0295434","article-title":"Five-year clinical outcomes of 107 consecutive DMEK surgeries","volume":"18","author":"Bichet","year":"2023","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.survophthal.2025.09.024_bib14","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/01.TP.0000158022.62059.F2","article-title":"Immunosuppression with cyclosporine a and mycophenolate mofetil after penetrating high-risk keratoplasty: a retrospective study","volume":"79","author":"Birnbaum","year":"2005","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.survophthal.2025.09.024_bib15","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1055\/s-2008-1027129","article-title":"Basiliximab following penetrating risk-keratoplasty--a prospective randomized pilot study","volume":"225","author":"Birnbaum","year":"2008","journal-title":"Klin Monbl Augenheilkd"},{"issue":"11","key":"10.1016\/j.survophthal.2025.09.024_bib16","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1038\/eye.2008.402","article-title":"Mycophenolate mofetil (MMF) following penetrating high-risk keratoplasty: Long-term results of a prospective, randomised, multicentre study","volume":"23","author":"Birnbaum","year":"2009","journal-title":"Eye"},{"issue":"5","key":"10.1016\/j.survophthal.2025.09.024_bib17","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/01.tp.0000191291.71003.1b","article-title":"An open prospective pilot study on the use of rapamycin after penetrating high-risk keratoplasty","volume":"81","author":"Birnbaum","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.survophthal.2025.09.024_bib18","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s00347-007-1512-2","article-title":"Inhibition of angiogenesis in the anterior chamber of the eye","volume":"104","author":"Bock","year":"2007","journal-title":"Ophthalmologe"},{"issue":"15","key":"10.1016\/j.survophthal.2025.09.024_bib19","doi-asserted-by":"crossref","first-page":"6554","DOI":"10.1167\/iovs.15-18526","article-title":"Identification of novel endogenous anti (lymph) angiogenic factors in the aqueous humor","volume":"57","author":"Bock","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.survophthal.2025.09.024_bib20","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.survophthal.2012.01.007","article-title":"Corneal neovascularization: an anti-VEGF therapy review","volume":"57","author":"Chang","year":"2012","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.09.024_bib21","doi-asserted-by":"crossref","first-page":"1000256","DOI":"10.4172\/2155-9899.1000256","article-title":"Corneal lymphatics: role in ocular inflammation as inducer and responder of adaptive immunity","volume":"5","author":"Chauhan","year":"2014","journal-title":"J Clin Cell Immunol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.09.024_bib22","doi-asserted-by":"crossref","first-page":"148","DOI":"10.4049\/jimmunol.182.1.148","article-title":"Levels of Foxp3 in regulatory t cells reflect their functional status in transplantation","volume":"182","author":"Chauhan","year":"2009","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.survophthal.2025.09.024_bib23","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1167\/iovs.08-1997","article-title":"Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis","volume":"50","author":"Chen","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.survophthal.2025.09.024_bib24","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/s41598-021-03952-y","article-title":"VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin c in metastatic colorectal cancer","volume":"12","author":"Chionh","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.survophthal.2025.09.024_bib25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10792-007-9099-9","article-title":"Graft failure IV. Immunologic mechanisms of corneal transplant rejection","volume":"28","author":"Chong","year":"2008","journal-title":"Int Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2025.09.024_bib26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/01.ICL.0000062460.03555.32","article-title":"Topical cyclosporine in pediatric keratoplasty","volume":"29","author":"Cosar","year":"2003","journal-title":"Eye Contact Lens"},{"issue":"5","key":"10.1016\/j.survophthal.2025.09.024_bib27","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.ophtha.2013.12.017","article-title":"Contributors ACGR. A comparison of lamellar and penetrating keratoplasty outcomes: a registry study","volume":"121","author":"Coster","year":"2014","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.survophthal.2025.09.024_bib28","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.autrev.2015.12.001","article-title":"The autoimmune diseases of the eyes","volume":"15","author":"de Andrade","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.survophthal.2025.09.024_bib29","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00417-014-2851-8","article-title":"Three-year corneal graft survival rate in high-risk cases treated with subconjunctival and topical bevacizumab","volume":"253","author":"Dekaris","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.09.024_bib30","doi-asserted-by":"crossref","first-page":"698","DOI":"10.4103\/ijo.IJO_1964_22","article-title":"Graft rejection in component keratoplasty","volume":"71","author":"Deshmukh","year":"2023","journal-title":"Indian J Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2025.09.024_bib31","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.survophthal.2016.12.010","article-title":"Management of high-risk corneal transplantation","volume":"62","author":"Di Zazzo","year":"2017","journal-title":"Surv Ophthalmol"},{"issue":"8","key":"10.1016\/j.survophthal.2025.09.024_bib32","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.ophtha.2022.03.024","article-title":"Bevacizumab in high-risk corneal transplantation: a pilot multicenter prospective randomized control trial","volume":"129","author":"Dohlman","year":"2022","journal-title":"Ophthalmology"},{"issue":"46","key":"10.1016\/j.survophthal.2025.09.024_bib33","doi-asserted-by":"crossref","first-page":"46ra61","DOI":"10.1126\/scitranslmed.3001022","article-title":"A biosynthetic alternative to human donor tissue for inducing corneal regeneration: 24-month follow-up of a phase 1 clinical study","volume":"2","author":"Fagerholm","year":"2010","journal-title":"Sci Transl Med"},{"issue":"10","key":"10.1016\/j.survophthal.2025.09.024_bib34","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1038\/s41433-020-01375-z","article-title":"Topical 0.03% tacrolimus versus systemic mycophenolate mofetil as adjuncts to systemic corticosteroids for preventing graft rejection after repeat keratoplasty: one-year results of a randomized clinical trial","volume":"35","author":"Faramarzi","year":"2021","journal-title":"Eye"},{"issue":"2","key":"10.1016\/j.survophthal.2025.09.024_bib35","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10792-014-9938-4","article-title":"Subconjunctival and\/or intrastromal bevacizumab injections as preconditioning therapy to promote corneal graft survival","volume":"35","author":"Fasciani","year":"2015","journal-title":"Int Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2025.09.024_bib36","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/ICO.0b013e3182775f8d","article-title":"Topical ranibizumab as a treatment of corneal neovascularization","volume":"32","author":"Ferrari","year":"2013","journal-title":"Cornea"},{"issue":"4","key":"10.1016\/j.survophthal.2025.09.024_bib37","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/BF00154385","article-title":"Systemic acyclovir and penetrating keratoplasty for herpes simplex keratitis","volume":"80","author":"Foster","year":"1992","journal-title":"Doc Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2025.09.024_bib38","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.it.2017.11.007","article-title":"When clarity is crucial: regulating ocular surface immunity","volume":"39","author":"Foulsham","year":"2018","journal-title":"Trends Immunol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.09.024_bib39","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/ICU.0b013e3282fb7c33","article-title":"Polypoidal choroidal vasculopathy and treatments","volume":"19","author":"Gomi","year":"2008","journal-title":"Curr Opin Ophthalmol"},{"issue":"8","key":"10.1016\/j.survophthal.2025.09.024_bib40","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/00003226-200211000-00007","article-title":"Fluorescein-potentiated argon laser therapy improves symptoms and appearance of corneal neovascularization","volume":"21","author":"Gordon","year":"2002","journal-title":"Cornea"},{"issue":"6","key":"10.1016\/j.survophthal.2025.09.024_bib41","doi-asserted-by":"crossref","first-page":"e922","DOI":"10.1111\/aos.14708","article-title":"Causes of corneal transplant failure: a multicentric study","volume":"99","author":"G\u00f3mez-Benlloch","year":"2021","journal-title":"Acta Ophthalmol"},{"issue":"28","key":"10.1016\/j.survophthal.2025.09.024_bib42","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000011404","article-title":"Graft survival rate of deep anterior lamellar keratoplasty for keratoconus: a meta-analysis","volume":"97","author":"Guan","year":"2018","journal-title":"Med (Baltim)"},{"issue":"1","key":"10.1016\/j.survophthal.2025.09.024_bib43","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S0161-6420(13)31253-6","article-title":"Systemic cyclosporine in high-risk keratoplasty: short-versus long-term therapy","volume":"101","author":"Hill","year":"1994","journal-title":"Ophthalmology"},{"issue":"Pt 4","key":"10.1016\/j.survophthal.2025.09.024_bib44","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/eye.1995.99","article-title":"Systemic cyclosporine in high-risk keratoplasty: long-term results","volume":"9","author":"Hill","year":"1995","journal-title":"Eye"},{"issue":"5","key":"10.1016\/j.survophthal.2025.09.024_bib45","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000000894","article-title":"Risk of corneal graft rejection after high-risk keratoplasty following fine-needle vessel coagulation of corneal neovascularization combined with bevacizumab: a pilot study","volume":"5","author":"Hos","year":"2019","journal-title":"Transpl Direct"},{"issue":"3","key":"10.1016\/j.survophthal.2025.09.024_bib46","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1167\/iovs.15-17551","article-title":"Graft site microenvironment determines dendritic cell trafficking through the CCR7-CCL19\/21 axis","volume":"57","author":"Hua","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"10.1016\/j.survophthal.2025.09.024_bib47","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1136\/bjo.2009.172577","article-title":"Efficacy of topical ciclosporin a for treatment and prevention of graft rejection in corneal grafts with previous rejection episodes","volume":"94","author":"Javadi","year":"2010","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.09.024_bib48","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/bjo.2006.097428","article-title":"Tacrolimus immunosuppression in high-risk corneal grafts","volume":"91","author":"Joseph","year":"2007","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.09.024_bib49","article-title":"Immune privilege and eye-derived T-regulatory cells","volume":"2018","author":"Keino","year":"2018","journal-title":"J Immunol Res"},{"issue":"4","key":"10.1016\/j.survophthal.2025.09.024_bib50","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1167\/iovs.15-17894","article-title":"High-risk corneal graft rejection in the setting of previous corneal herpes simplex virus (HSV)-1 infection","volume":"57","author":"Kuffova","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2025.09.024_bib51","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s00417-002-0496-5","article-title":"Risk factors for corneal allograft rejection: intermediate results of a prospective normal-risk keratoplasty study","volume":"240","author":"K\u00fcchle","year":"2002","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"11","key":"10.1016\/j.survophthal.2025.09.024_bib52","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.humimm.2003.08.346","article-title":"Expression of HLA-G in human cornea, an immune-privileged tissue","volume":"64","author":"Le Discorde","year":"2003","journal-title":"Hum Immunol"},{"issue":"7","key":"10.1016\/j.survophthal.2025.09.024_bib53","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00417-015-3008-0","article-title":"Adverse effects of low-dose systemic cyclosporine therapy in high-risk penetrating keratoplasty","volume":"253","author":"Lee","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2025.09.024_bib54","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.ajo.2011.05.002","article-title":"Deep anterior lamellar keratoplasty using acellular corneal tissue for prevention of allograft rejection in high-risk corneas","volume":"152","author":"Li","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"10.1016\/j.survophthal.2025.09.024_bib55","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1136\/bjophthalmol-2013-303639","article-title":"Topical 0.03% tacrolimus preventing rejection in high-risk corneal transplantation: a cohort study","volume":"97","author":"Magalhaes","year":"2013","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"10.1016\/j.survophthal.2025.09.024_bib56","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1097\/ICO.0b013e31821e65b3","article-title":"Efficacy of postoperative immunosuppression after keratoplasty in herpetic keratitis","volume":"30","author":"Maier","year":"2011","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2025.09.024_bib57","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00417-006-0410-7","article-title":"Clear graft survival and immune reactions following emergency keratoplasty","volume":"245","author":"Maier","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.09.024_bib58","first-page":"1016","article-title":"Predicting the risk for corneal graft rejection by aqueous humor analysis","volume":"17","author":"Maier","year":"2011","journal-title":"Mol Vis"},{"issue":"12","key":"10.1016\/j.survophthal.2025.09.024_bib59","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s00417-003-0724-7","article-title":"Synergistic antiherpetic effect of acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease: first results of a randomised pilot study","volume":"241","author":"Mayer","year":"2003","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2025.09.024_bib60","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1177\/1120672120947592","article-title":"Corneal graft surgery: a monocentric long-term analysis","volume":"31","author":"Montesel","year":"2021","journal-title":"Eur J Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2025.09.024_bib61","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/ACI.0b013e32833dfa11","article-title":"High-risk corneal allografts and why they lose their immune privilege","volume":"10","author":"Niederkorn","year":"2010","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.09.024_bib62","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/08830185.2012.737877","article-title":"Corneal transplantation and immune privilege","volume":"32","author":"Niederkorn","year":"2013","journal-title":"Int Rev Immunol"},{"issue":"5","key":"10.1016\/j.survophthal.2025.09.024_bib63","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1600-6143.2011.03948.x","article-title":"Role of lentivirus-mediated overexpression of programmed death-ligand 1 on corneal allograft survival","volume":"12","author":"Nosov","year":"2012","journal-title":"Am J Transpl"},{"issue":"9","key":"10.1016\/j.survophthal.2025.09.024_bib64","doi-asserted-by":"crossref","first-page":"4571","DOI":"10.1182\/blood-2007-10-120337","article-title":"Inhibition of endogenous TGF-\u03b2 signaling enhances lymphangiogenesis","volume":"111","author":"Oka","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.survophthal.2025.09.024_bib65","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/ICO.0b013e3182542613","article-title":"Vascular endothelial growth factor inhibitors for treatment of corneal neovascularization: a meta-analysis","volume":"32","author":"Papathanassiou","year":"2013","journal-title":"Cornea"},{"issue":"3","key":"10.1016\/j.survophthal.2025.09.024_bib66","first-page":"17","article-title":"Penetrating keratoplasty in high-risk children: prevention of graft rejection","volume":"130","author":"Pleskova","year":"2014","journal-title":"Vestn Oftalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2025.09.024_bib67","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1158\/2326-6066.CIR-16-0193","article-title":"Regulatory t cells: differentiation and function","volume":"4","author":"Plitas","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"10.1016\/j.survophthal.2025.09.024_bib68","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1136\/bjo.85.12.1464","article-title":"Systemic cyclosporin a in high risk penetrating keratoplasties: a case-control study","volume":"85","author":"Poon","year":"2001","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2025.09.024_bib69","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.ophtha.2018.03.050","article-title":"Five-year graft survival of descemet membrane endothelial keratoplasty (EK) versus descemet stripping EK and the effect of donor sex matching","volume":"125","author":"Price","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2025.09.024_bib70","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1097\/ICO.0000000000000505","article-title":"Evolution of endothelial keratoplasty: where are we headed?","volume":"34","author":"Price","year":"2015","journal-title":"Cornea"},{"issue":"9","key":"10.1016\/j.survophthal.2025.09.024_bib71","first-page":"006","article-title":"Corneal allograft rejection: immunopathogenesis to therapeutics","volume":"2013","author":"Qazi","year":"2013","journal-title":"J Clin Cell Immunol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.09.024_bib72","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12886-022-02318-w","article-title":"Topical administration of tacrolimus and corticosteroids in tapering doses is effective in preventing immune rejection in high-risk keratoplasty: a 5-year follow-up study","volume":"22","author":"Qi","year":"2022","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.09.024_bib73","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/01.ico.0000178731.42187.46","article-title":"Prevention and treatment of corneal graft rejection: current practice patterns (2004)","volume":"25","author":"Randleman","year":"2006","journal-title":"Cornea"},{"issue":"1","key":"10.1016\/j.survophthal.2025.09.024_bib74","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1517\/14656566.2013.751374","article-title":"Tacrolimus in transplant rejection","volume":"14","author":"Rath","year":"2013","journal-title":"Expert Opin Pharm"},{"issue":"6","key":"10.1016\/j.survophthal.2025.09.024_bib75","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1432-2277.2005.00126.x","article-title":"Systemic mycophenolate mofetil avoids immune reactions in penetrating high-risk keratoplasty: preliminary results of an ongoing prospectively randomized multicentre study","volume":"18","author":"Reinhard","year":"2005","journal-title":"Transpl Int"},{"issue":"5","key":"10.1016\/j.survophthal.2025.09.024_bib76","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s004170100285","article-title":"Systemic mycophenolate mofetil in comparison with systemic cyclosporin a in high-risk keratoplasty patients: 3 years' results of a randomized prospective clinical trial","volume":"239","author":"Reinhard","year":"2001","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"11","key":"10.1016\/j.survophthal.2025.09.024_bib77","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1136\/bjo.83.11.1268","article-title":"Mycophenolate mofetil versus cyclosporin a in high risk keratoplasty patients: a prospectively randomised clinical trial","volume":"83","author":"Reis","year":"1999","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.09.024_bib78","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1055\/s-2001-13078","article-title":"Highly active antiviral and immunosuppressive therapy following keratoplasty in patients with herpetic eye disease","volume":"218","author":"Reis","year":"2001","journal-title":"Klin Monbl Augenheilkd"},{"key":"10.1016\/j.survophthal.2025.09.024_bib79","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ajo.2021.10.031","article-title":"Corneal endothelial transplantation in uveitis: incidence and risk factors","volume":"236","author":"Roldan","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.09.024_bib80","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/5372090","article-title":"Corneal allografts: factors for and against acceptance","volume":"2021","author":"Sakowska","year":"2021","journal-title":"J Immunol Res"},{"issue":"8","key":"10.1016\/j.survophthal.2025.09.024_bib81","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1136\/bjophthalmol-2011-301349","article-title":"Penetrating keratoplasty versus deep anterior lamellar keratoplasty: comparison of optical and visual quality outcomes","volume":"96","author":"Sar\u0131","year":"2012","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2025.09.024_bib82","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/ICO.0000000000002406","article-title":"Corneal crosslinking to regress pathologic corneal neovascularization before high-risk keratoplasty","volume":"40","author":"Schaub","year":"2021","journal-title":"Cornea"},{"issue":"5","key":"10.1016\/j.survophthal.2025.09.024_bib83","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.3390\/jcm9051280","article-title":"Immunomodulatory strategies targeting dendritic cells to improve corneal graft survival","volume":"9","author":"Sch\u00f6nberg","year":"2020","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.survophthal.2025.09.024_bib84","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ajo.2011.05.020","article-title":"Survival of mushroom keratoplasty performed in corneas with postinfectious vascularized scars","volume":"153","author":"Scorcia","year":"2012","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2025.09.024_bib85","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.ophtha.2012.09.035","article-title":"A novel cyclosporine a drug-delivery system for prevention of human corneal rejection after high-risk keratoplasty: a clinical study","volume":"120","author":"Shi","year":"2013","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.survophthal.2025.09.024_bib86","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ajo.2011.01.019","article-title":"Prospective, randomized study of the efficacy of systemic cyclosporine in high-risk corneal transplantation","volume":"152","author":"Shimazaki","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.09.024_bib87","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12886-024-03506-6","article-title":"Topical tacrolimus for high-risk corneal transplantation: a randomized, clinical trial","volume":"24","author":"Shimazaki","year":"2024","journal-title":"BMC Ophthalmol"},{"issue":"8","key":"10.1016\/j.survophthal.2025.09.024_bib88","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00417-010-1388-8","article-title":"Efficacy of topical cyclosporine a 2% in prevention of graft rejection in high-risk keratoplasty: a randomized controlled trial","volume":"248","author":"Sinha","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.09.024_bib89","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jcjo.2019.07.010","article-title":"Outcomes of difluprednate treatment for corneal graft rejection","volume":"55","author":"Sorkin","year":"2020","journal-title":"Can J Ophthalmol"},{"issue":"52","key":"10.1016\/j.survophthal.2025.09.024_bib90","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1556\/OH.2013.29791","article-title":"Postoperative therapy of penetrating keratoplasty in herpes simplex keratitis","volume":"154","author":"S\u00fcveges","year":"2013","journal-title":"Orv Hetil"},{"issue":"2","key":"10.1016\/j.survophthal.2025.09.024_bib91","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/08923970600809447","article-title":"Comparison of FK 506, mycophenolate mofetil, and aminoguanidine effects on delay of corneal allograft rejection in an experimental model of low-risk and high-risk keratoplasty","volume":"28","author":"Svoz\u00edlkov\u00e1","year":"2006","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.09.024_bib92","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/TP.0000000000001044","article-title":"In vivo expansion of regulatory t cells by low-dose interleukin-2 treatment increases allograft survival in corneal transplantation","volume":"100","author":"Tahvildari","year":"2016","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.survophthal.2025.09.024_bib93","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/archopht.117.4.445","article-title":"PR. Oral acyclovir after penetrating keratoplasty for herpes simplex keratitis","volume":"117","author":"Cohen","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2025.09.024_bib94","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000099255","article-title":"Ocular immunosuppressive microenvironment","volume":"92","author":"Taylor","year":"2007","journal-title":"Chem Immunol Allergy"},{"issue":"3","key":"10.1016\/j.survophthal.2025.09.024_bib95","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.transproceed.2007.01.066","article-title":"Human leukocyte antigen and its role in transplantation biology","volume":"39","author":"Trivedi","year":"2007","journal-title":"Transpl Proc"},{"issue":"3","key":"10.1016\/j.survophthal.2025.09.024_bib96","doi-asserted-by":"crossref","first-page":"193S","DOI":"10.1016\/S0041-1345(03)00234-3","article-title":"Sirolimus in liver transplantation","volume":"35","author":"Trotter","year":"2003","journal-title":"Transpl Proc"},{"issue":"10","key":"10.1016\/j.survophthal.2025.09.024_bib97","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1136\/bjo.2008.143024","article-title":"Evaluation of topical ciclosporin 0.05% for prevention of rejection in high-risk corneal grafts","volume":"92","author":"\u00dcnal","year":"2008","journal-title":"Br J Ophthalmol"},{"issue":"19","key":"10.1016\/j.survophthal.2025.09.024_bib98","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.3390\/jcm11195511","article-title":"Management and treatment outcomes of high-risk corneal transplantations","volume":"11","author":"Urba\u0144ska","year":"2022","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.survophthal.2025.09.024_bib99","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1167\/iovs.13-11799","article-title":"A fish scale\u2013derived collagen matrix as artificial cornea in rats: properties and potential","volume":"54","author":"van Essen","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.survophthal.2025.09.024_bib100","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ajo.2020.04.005","article-title":"Descemet membrane endothelial keratoplasty: Ten-year graft survival and clinical outcomes","volume":"217","author":"Vasiliauskait\u0117","year":"2020","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.09.024_bib101","article-title":"Five-year follow-up outcomes after descemet's stripping automated endothelial keratoplasty: a retrospective study","volume":"5","author":"Wakimasu","year":"2020","journal-title":"BMJ Open Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2025.09.024_bib102","first-page":"160","article-title":"Studies on the effects of the immunosuppressant FK-506 on the high-risk corneal graft rejection","volume":"18","author":"Wang","year":"2002","journal-title":"Yan Ke Xue Bao"},{"issue":"1","key":"10.1016\/j.survophthal.2025.09.024_bib103","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/s41598-025-85138-4","article-title":"Ten-year outcomes after DMEK, DSAEK, and PK: insights on graft survival, endothelial cell density loss, rejection and visual acuity","volume":"15","author":"Wilhelm","year":"2025","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.survophthal.2025.09.024_bib104","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1097\/01.tp.0000185197.37824.35","article-title":"How effective is penetrating corneal transplantation? Factors influencing long-term outcome in multivariate analysis","volume":"81","author":"Williams","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.survophthal.2025.09.024_bib105","doi-asserted-by":"crossref","DOI":"10.12659\/AOT.945388","article-title":"Risk factors for graft failure after penetrating keratoplasty in eastern China from 2018 to 2021","volume":"29","author":"Yang","year":"2024","journal-title":"Ann Transpl"},{"issue":"4","key":"10.1016\/j.survophthal.2025.09.024_bib106","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/ICU.0000000000000767","article-title":"Advances in corneal graft rejection","volume":"32","author":"Yin","year":"2021","journal-title":"Curr Opin Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2025.09.024_bib107","doi-asserted-by":"crossref","first-page":"10","DOI":"10.5500\/wjt.v6.i1.10","article-title":"High-risk corneal allografts: a therapeutic challenge","volume":"6","author":"Yu","year":"2016","journal-title":"World J Transpl"},{"issue":"9","key":"10.1016\/j.survophthal.2025.09.024_bib108","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/s41433-019-0717-3","article-title":"Observation of topical tacrolimus on high-risk penetrating keratoplasty patients: a randomized clinical trial study","volume":"34","author":"Zhai","year":"2020","journal-title":"Eye"},{"issue":"5","key":"10.1016\/j.survophthal.2025.09.024_bib109","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3923\/ijp.2023.701.707","article-title":"Comparative study of staged optimized immunosuppressive regimen with conventional regimen in high-risk corneal transplantation","volume":"19","author":"Zhang","year":"2023","journal-title":"Int J Pharm"},{"issue":"7","key":"10.1016\/j.survophthal.2025.09.024_bib110","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1167\/iovs.08-1899","article-title":"Depletion of passenger leukocytes from corneal grafts: an effective means of promoting transplant survival?","volume":"50","author":"Zhang","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625725001821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625725001821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T18:02:34Z","timestamp":1768845754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625725001821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":110,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0039625725001821"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2025.09.024","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical and surgical approaches to prevent corneal graft rejection in high-risk recipients","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2025.09.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}